LENSAR (NASDAQ:LNSR) 주식

LENSAR

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

LENSAR Inc

News

ERIC

Ericsson To Sell Up To 60% Of Vested LTV 2022 Shares To Settle Withholding Taxes And Social Security Costs

Vertiv Accelerates AI Data Center Evolution With High-Efficiency 800 VDC Solutions Aligned To NVIDIA's Future AI Roadmap

NVDA

HPE Expands NVIDIA Collaboration With AI Factory-Ready Cloud, Storage, And Compute Platforms Featuring RTX PRO 6000 Blackwell GPU Support

NTAP

NetApp Integrates NVIDIA AI Data Platform Into AIPod To Accelerate Agentic AI And Retrieval-Augmented Generation

SMCI

Supermicro Expands AI Portfolio With RTX PRO 6000 Blackwell Systems, Supporting NVIDIA Enterprise AI Factory Validated Designs

Former Vice President&nbsp;Mike Pence&nbsp;has lauded&nbsp;President Donald Trump&#8216;s Middle East visit for its beneficial effects on the U.S. economy, despite his criticism of the diplomatic aspects of the trip. 
What Happened:&nbsp;&nbsp;Despite a public fallout with Trump over the&nbsp;2020 presidential election certification and the ensuing Capitol riot on January 6, 2021, Pence spoke positively of Trump&#8217;s Middle East trip&#8217;s impact on the American economy during an NBC&#8217;s &#8220;Meet the Press&#8221; interview on Sunday. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Exclusive Interview: Mike Pence says he privately warned Trump against tariffs in his first term" width="500" height="281" src="https://www.youtube.com/embed/LzCiUDJyYAw?start=524&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Pence described the journey as &#8220;very successful&#8221; for the U.S. economy. &#8220;The&nbsp;president secured financial commitments in&nbsp;all three countries, including a&nbsp;historic contract for purchasing Boeing&nbsp;aircraft that&#8217;ll really support American jobs,&#8221; Pence said.
These comments from the former Indiana governor are noteworthy, given his recent strained relationship with Trump and recent criticisms of the President&#8217;s <a href="https://www.benzinga.com/news/25/05/45214328/mike-pence-warns-trumps-indiscriminate-tariffs-could-trigger-price-shock-and-potential-shortages-keeping-our-kids-toys-affordable-is-part-of-the-american-dream">sweeping tariffs</a>.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/05/45486452/jim-cramer-recalls-2011s-6-7-market-decline-after-us-debt-downgrade-says-it-ultimately-meant-not" target="_blank" rel="noreferrer noopener">Jim Cramer Recalls 2011&#8217;s 6.7% Market Decline After US Debt Downgrade, Says It &#8216;Ultimately Meant Nothing:&#8217; Dan Niles Sees Limited Downside Amid Tariff Rollbacks, FOMO</a>
Why It Matters: Trump&#8217;s Middle East visit, which Pence praises, saw the signing of deals worth <a href="https://www.benzinga.com/25/05/45462404/trump-unveils-over-200-billion-worth-of-deals-with-uae-including-major-etihad-airways-commitment">over $200 billion </a>between the U.S. and the United Arab Emirates (UAE). A significant part of these deals involved a $14.5 billion commitment from&nbsp;Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>),&nbsp;GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), and Etihad Airways. 
Additionally, Trump secured a $1.2 trillion economic agreement with Qatar, including a <a href="https://www.benzinga.com/government/regulations/25/05/45446924/trump-secures-12-trillion-qatar-deal-as-boeing-ge-land-record-orders">record-breaking</a> $96 billion order from Qatar Airways for Boeing and GE Aerospace.
According to CNN, several Democrats, usually critical of President Trump, praised his decision to lift longstanding sanctions on Syria and engage with its new leader. They saw it as a potential economic boost for Syria and a way to reshape the region. Support came from figures like Leon Panetta, Rep. Jim Himes (D-Conn.) and Sen. Chris Murphy (D-Conn.), with Himes reluctantly admitting Trump managed much of the Middle East trip effectively. Murphy, however, criticized Trump for accepting the luxury Qatari jet.
On the other hand, economist Peter Schiff warned that Qatar&#8217;s $200 billion deal with Boeing <a href="https://www.benzinga.com/general/travel/25/05/45427289/peter-schiff-warns-qatars-200-billion-boeing-deal-could-spike-us-inflation-interest-rates-says-treasury-sell-off-may-follow">could lead </a>to a surge in U.S. inflation and interest rates. He states that to help finance the purchase, "Qatar will likely sell a lot of Treasuries and other U.S. assets," which would further strain the U.S. bond market, already under pressure.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/tech/25/05/45485055/elon-musks-ex-girlfriend-grimes-questions-mark-zuckerbergs-aptitude-for-metaverse-leadership-says-zuckerberg" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Ex-Girlfriend Grimes Questions Mark Zuckerberg&#8217;s Aptitude For Metaverse Leadership, Says Zuckerberg Is &#8216;Wildly Under Qualified&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Trump's Middle East Trip Draws Rare Praise From Mike Pence As 'Very Successful' For US Economy Amid 'Historic' Boeing Deal: 'That'll Really Support American Jobs'

CRWD

CrowdStrike And NVIDIA Partner To Secure Full AI Lifecycle With Integrated Falcon Platform In Enterprise AI Factory Deployments

MRVL

Marvell And NVIDIA Team Up To Deliver Custom AI Infrastructure With Nvlink Fusion, Enabling Hyperscaler-Grade Flexibility And Speed

Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) Skunk Works and the Danish Ministry of Defence (MOD) completed a successful live <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429984-1&amp;h=3420190264&amp;u=https%3A%2F%2Fwww.lockheedmartin.com%2Fen-us%2Fproducts%2Ff-35%2Ff-35-about.html&amp;a=F-35">F-35</a> interoperability demonstration. This is another success in a series of Multi-Domain Operations (MDO) demonstrations proving the F-35's ability to serve as a powerful force multiplier, enabling allied forces to rapidly deploy ready-now capabilities to connect systems across the battlespace.
&nbsp;
Danish F-35s flying out of Fort Worth, Texas, shared classified data via DAGGR-2, a Skunk Works' Open Systems Gateway (OSG) developed under a partnership with the Missile Defense Agency (MDA), through commercial satellite communications and displayed at Skrydstrup Air Base in Denmark.

Lockheed's F-35 Shares Classified Data Across Continents in New Allied Demo With Denmark

<a href="https://www.globenewswire.com/Tracker?data=95ttCcrFviRqrRp3UsJTOWq67jNPTSKrVo1T8y4V65E_XLeHk__aAnyrGHzuO5kcM2MndMWx2QPViGsNwnaqvpO9LgQHVoNIPZSjyk3BOYY=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA))), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United States, VeriSight Pro brings real-time 3D imaging directly inside the heart, helping physicians perform procedures with greater clarity — without the need for general anesthesia. Designed for procedures such as transcatheter valve repair and left atrial appendage closure, VeriSight Pro offers high-resolution 2D and 3D visualization directly within the heart chambers. This enables confident clinical decision-making in structural heart and electrophysiology interventions, while removing the need for general anesthesia and associated risks.

Philips Launches 3D Heart Imaging Catheter In Europe to Boost Precision, Cut Anesthesia Use

Earnings

Niu Technologies Q1 Adj. EPADS $(0.05) Up From $(0.10) YoY, Sales $93.98M Up From $69.91M YoY

Willy Woo, a widely followed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) influencer and analyst, revealed the series of events Sunday that caused them to close a business that was making him &#8220;millions per year.&#8221;
What Happened:&nbsp;In an X thread, Woo shared the journey about The Bitcoin Forecast, a subscription-based content offering on Substack that analyzed BTC&#8217;s on-chain signals and predicted the future course of the market.
The Bitcoin Forecast, which started in October 2020, quickly gained traction, according to Woo, prompting them to get BTC payments integrated for subscriptions.
&#8220;By 6 months I had almost 10,000 paid subs. I&#8217;m pretty sure even today it&#8217;s the most successful BTC investment letter to date,&#8221; Woo said. 
Benzinga couldn&#8217;t independently verify these claims. Substack didn&#8217;t immediately return a request for comment.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Exactly 3 years ago I shut down a business making me millions per year. Here&#39;s a &#x1f9f5;on how it started, why I shut it down and why I&#39;m helping to build something better for this industry.
&mdash; Willy Woo (@woonomic) <a href="https://twitter.com/woonomic/status/1924227623074554195?ref_src=twsrc%5Etfw">May 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45427302/anthony-scaramucci-forecasts-bitcoin-will-be-deemed-asset-class-akin-to-gold-when-it-reaches-500000">Anthony Scaramucci Says Once Bitcoin Hits $500,000 It Will Be Considered An Asset Class Just Like Gold</a> 
However, things started to change after BTC surpassed the $60,000 mark. Woo noticed a shift in the market, with the market beginning to heavily rely on derivatives, which were not being adequately represented by on-chain signaling.
The result-the letter which launched with a reliability of 83%, saw its reliability dip below 60%.
&#8220;When reliability dropped below 60%,&nbsp;I felt it was doing&nbsp;more harm than good, so&nbsp;I killer the letter. It&nbsp;was no longer suitable for&nbsp;its mission,&#8221; Woo said. &#8220;It was encouraging&nbsp;retail to play timing games&nbsp;and without disciplined risk management&nbsp;plebs were effectively gambling.&#8221;
Woo&#8217;s decision underscores the volatility and unpredictability of the Bitcoin market. 
Benzinga&#8217;s Take: While on-chain fundamentals often focus on measuring the intrinsic value of a cryptocurrency using data derived directly from the blockchain, derivatives could help traders hedge against price movements, protecting positions while boosting stability and liquidity. A comprehensive analysis should involve informed understanding of both these sets of metrics.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/cryptocurrency/25/05/45486583/michael-saylors-tip-to-grow-wealth-by-100x-dont-quit-jobs-invest-in-bitcoin-over-obscenely" target="_blank" rel="noreferrer noopener">Michael Saylor Has A Tip For Average People Looking To Grow Their Wealth By 100x, But He Doesn&#8217;t Want You To Quit Your Job To Invest In Bitcoin</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Photo Courtesy: Wirestock Creators on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Top Bitcoin Analyst Reveals Why They Shut Down Their Business That Was Making 'Millions Per Year'

FRSX

Trading Halt: Halted at 3:58:28 a.m. ET - Trading Halt: Halt News Pending

RKLB

Reported Saturday, Rocket Lab Completes Third Mission For iQPS With 100% Success In 2025, Next Launch Scheduled for June

Palmer Luckey says the arms race is no longer about bigger missiles but autonomous weapons that operate using artificial intelligence and he wants the United States to be "the world gun store" that supplies them.
What Happened: The Anduril founder <a href="https://www.cbsnews.com/news/palmer-luckey-ai-powered-autonomous-weapons-future-of-warfare-60-minutes-transcript/">told</a> CBS' 60 Minutes that commercial tech has surpassed the Pentagon, arguing that a Tesla has better AI than any U.S. aircraft and a Roomba has better autonomy than most Pentagon weapons systems.
"Right now, there are so many weapon systems that require manning… If I can have one guy command and controlling 100 aircraft, that's a lot easier," Luckey said.
Though he conceded the idea of autonomous weapons "is a scary idea," he insisted, "that's the world we live in." He added, "There's no moral high ground to making a land mine that can't tell the difference between a school bus full of children and Russian armor."
See also: <a href="https://www.benzinga.com/25/05/45487522/tesla-is-accepting-trade-ins-for-2024-cybertruck-amid-plummeting-sales-figures-report">Tesla Is Accepting Trade-Ins For 2024 Cybertruck Amid Plummeting Sales: Report</a>
Luckey says the Costa Mesa, California, company will top $6 billion in <a href="https://www.benzinga.com/news/24/08/40280155/lockheed-martin-boeing-and-northrop-grumman-rival-anduril-led-by-peter-thiels-venture-capital-raises">defense contracts</a> by year-end after beating legacy primes for Air Force and Special Operations deals. "We're gonna be making large numbers of cruise missiles, large numbers of fighter jets… day 100," he told CBS.
U.N. Secretary-General António Guterres has labeled fully autonomous lethal weapons "politically unacceptable and morally repugnant" and <a href="https://press.un.org/en/2025/sgsm22643.doc.htm">wants a treaty</a> banning them by 2026. Luckey counters: "It's not a question between smart weapons and no weapons. It's a question between smart weapons and dumb weapons."
The 32-year-old sold Oculus to Facebook for $2 billion in 2014 and was <a href="https://www.benzinga.com/news/24/10/41269578/mark-zuckerbergs-meta-and-oculus-founder-palmer-luckey-mend-fences-the-people-responsible-arent-even">fired two years later</a> after a $9,000 political donation sparked controversy — an ouster that <a href="https://www.benzinga.com/news/24/04/38246351/meta-cto-gets-called-out-by-founder-of-company-building-electronic-border-wall-you-arent-credible">Facebook denies</a>.
Photo Courtesy: Anggalih Prasetya On Shutterstock.com
Read next: <a href="https://www.benzinga.com/25/05/45487650/nvidia-tsmc-and-apple-supplier-foxconn-partner-to-develop-taiwan-ai-supercomputer">Nvidia, TSMC And Apple Supplier Foxconn Partner To Develop Taiwan AI Supercomputer</a>

Emerging Markets

America Must Shift Roles From 'World Police' To 'World Gun Store,' Says Palmer Luckey

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin –
– Additional 42-Month Data Reinforce Vutrisiran's Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality –
– Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart Failure Visits by 46% in the Overall Patient Population During the Double-Blind Period –
– Findings Simultaneously Published in JACC –
– Details of TRITON-CM Phase 3 Study Evaluating Alnylam's Investigational Next-Generation TTR Silencer, Nucresiran, to be Presented at Congress –

ALNY

Reported Saturday, Alnylam's Vutrisiran Reduces All-Cause And Cardiovascular Mortality By Over 30% In ATTR-CM Patients, New 42-Month HELIOS-B Data Show

After Donald Trump signed an <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time">executive order</a> slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies facing the potential of compressed margins amid poor pricing power.
What Happened: According to Thomas Shipp, the head of equity research at LPL Financial, the pressure that the <a href="https://www.benzinga.com/news/25/05/45389750/trump-claims-drug-price-crackdown-could-slash-your-prescription-costs-by-59-but-will-big-pharma-fight-it-again">pharmaceutical manufacturers</a> are facing to lower prices domestically, &#8220;has the potential to compress margins by eroding pricing power and would provide a significant headwind to drug manufacturer share prices.&#8221;
However, he explains that the &#8220;middlemen&#8221; or PBMs that facilitate drug distribution and negotiate with pharmaceutical drug manufacturers to lower prescription costs have come under scrutiny for opaque pricing practices, like retaining rebates from drug manufacturers and "spread pricing."
&#8220;PBMs pay pharmacies less than what they charge health plan participants for drugs,&#8221; he said.
Another April 15 <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">executive order</a> signed by Trump called for increased transparency into PBM fees and requested that the role of these middlemen be reevaluated.
CVS Caremark, owned by CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Express Scripts, owned by Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and OptumRx, owned by UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), are the biggest PBM companies.
Shipp also underscored that PBM savings are expected, but direct price controls pose a longer-term risk for U.S.-heavy drugmakers. Transparency will reveal if PBM margin erosion can prevent deeper manufacturer cuts, he highlights.
&#8220;While many questions remain about how these executive orders will be implemented, after the initial news flow is digested, the net effect appears less detrimental to pharmaceutical drug manufacturers than to PBMs,&#8221; said Shipp.
&#8220;That said, reworking the way Americans buy their medicine is going to take a long time. Along the way, efforts to support direct-to-consumer sales will support both the manufacturers leading the charge and those they partner with for distribution,&#8221; he added.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45465955/ark-invest-takes-swipe-at-mstr-mara-says-bitcoin-treasury-companies-dont-make-sense-fundin">Ark Invest Expert Takes Swipe At MSTR, MARA, Says &#8216;Bitcoin Treasury Companies Don&#8217;t Make Sense:&#8217; &#8216;Funding Purchases With Debt&#8230;Seems Like A Recipe For Disaster&#8217;</a>
Why It Matters: Meanwhile, the billionaire investor and Shark Tank fame, Mark Cuban, called PBMs a &#8220;racket&#8221; in an X post by explaining that they <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">negotiate rebates and not prices</a>.
&#8220;They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#8217;t negotiate with anyone else. IMO, it&#8217;s a racket,&#8221; he said.
While the April 15 order calls for transparency in pricing, Cuban highlights that 30% of the $4.9 trillion in healthcare spending is attributed to the overhead insurance companies and pricing distortions big PBMs create.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One of the great lies the big PBM industry tells us is that they are needed to negotiate lower prices. It&#39;s a lie. They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#39;t negotiate with…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1923880717420986860?ref_src=twsrc%5Etfw">May 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Here are the aforementioned PBMs operating companies that have performed in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>41.41%</td>
<td>8.94%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>16.92%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.14%</td>
<td>-43.56%</td>
</tr>
</tbody>
</table>
</figure>
Here are a few pharma-linked ETFs for investors to consider.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-0.28%</td>
<td>-4.66%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-1.20%</td>
<td>-2.03%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.45%</td>
<td>-0.83%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.83%</td>
<td>-1.70%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>11.10%</td>
<td>1.65%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-6.51%</td>
<td>-6.89%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.63%</td>
<td>-24.07%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended higher on Friday. The SPY was up 0.63% to $594.20, while the QQQ advanced 0.44% to $521.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45433051/jim-cramer-says-gulf-countries-will-become-the-largest-hyperscalers-in-the-world-following-ai-deals">Jim Cramer Says Gulf Countries Will Become &#8216;Largest Hyperscalers In The World&#8217; After Nvidia&#8217;s 18,000 Blackwell Chip Deal</a></li>
</ul>
Photo courtesy: Rawpixel.com / Shutterstock.com

Health Care

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

As part of "Choose France," <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4430320-1&amp;h=1445138467&amp;u=https%3A%2F%2Fwww.kyndryl.com%2Ffr%2Ffr&amp;a=Kyndryl">Kyndryl</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>), a leading provider of mission-critical enterprise technology services, announced that it will invest up to €100 million over three years in France to strengthen the country's capabilities in data, artificial intelligence (AI) and cyber resilience.
&nbsp;
"I welcome the decision by Kyndryl, a leading player in enterprise technology services, in the expansion of their activities in France. This investment reflects the strength of our ecosystem, and the confidence France inspires when it comes to supporting ambitious technology projects. This initiative, facilitated by the teams of Business France, further reinforces our position as a leading innovation hub — built on world-class talent, a clear vision, and a stable, forward-looking environment," said Marie-Cécile Tardieu, Chief Operating Officer of Business France.

Kyndryl to Invest €100M in France to Boost AI, Data, and Cybersecurity Capabilities

<ul>
<li>Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs</li>
<li>Endoscopic ultrasound-guided delivery achieves targeted pancreatic expression in a large animal model with no toxicity observed to date</li>
<li>Data show nutrient-responsive GLP-1 secretion in human beta cells and human islets, demonstrating that Rejuva mimics natural hormone regulation rather than constant drug-driven stimulation</li>
<li>Rejuva advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected by June 2025</li>
</ul>

GUTS

Reported Saturday, Fractyl Health Showcases Preclinical Rejuva Data At ASGCT 2025 Demonstrating Durable Metabolic Benefits With Low Systemic GLP-1 Exposure

<ul>
<li>Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")</li>
<li>In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 days</li>
<li>TX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49%</li>
</ul>

TECX

Reported Saturday, Tectonic Therapeutic Presents Full Phase 1b Results For TX45 in PH-HFpEF Showing Sustained Hemodynamic Improvements And Strong Safety Profile

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AZEK, LNSR, DNB on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, TURN, DNB, GB on Behalf of Shareholders

Legal

LENSAR Reports First Quarter 2025 Results and Provides Business Update

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FARO, AVDX, LNSR on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, LNSR, AVDX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, DNB, BRDG on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SSBK, RDUS on Behalf of Shareholders

Small Cap

$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - DNB, BRDG, LNSR, SSBK

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, LNSR, TASK on Behalf of Shareholders

Comments

LENSAR

뉴스

파트너 / 기고자

벤징가 글로벌